BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lundbeck Inc. (LUN.CO) Presents New Data on Selincro From Three Phase III Studies That Consistently Show a Significant Reduction in Alcohol Consumption in Alcohol Dependent Patients With High Risk Drinking Level


4/8/2013 11:35:12 AM

Valby, 2013-04-08 08:00 CEST (GLOBE NEWSWIRE) --

• Patients treated with Selincro® (nalmefene) showed a reduction in total alcohol consumption after 6 months of 57% in study 1 (ESENSE 1)1 and 62% in study 2 (ESENSE 2)2 and after 12 months of 67% in study 3 (SENSE)3 among high risk drinking alcohol dependent patients.

• Selincro is the first and only medicine approved for the reduction of alcohol consumption in patients with alcohol dependence.4

•There is a significant unmet need as alcohol dependence is both underdiagnosed and undertreated. In Europe more than 90% of the patients with alcohol dependence are currently untreated.5,6

H. Lundbeck A/S (Lundbeck) announced today the results of the revised analysis of the Phase III programme that formed the basis for the approval of Selincro® (nalmefene) in the EU on February 25, 2013. Alcohol dependent patients with high risk drinking level (>60g/day for men, >40g/day for women) treated with Selincro showed a significant reduction in total alcohol consumption after 6 months of 57% in study 1 (ESENSE 1)1 and 62% in study 2 (ESENSE 2),2 and after 12 months of 67% in study 3 (SENSE).3 The analyses from these randomized, double-blind, placebo-controlled Phase III studies were presented at the 21st European Congress of Psychiatry (EPA) in Nice, France.



Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES